Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $53.89 Average PT from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received an average rating of “Buy” from the nine research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $57.88.

Several equities analysts have weighed in on the stock. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Scotiabank assumed coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price for the company. Wedbush raised their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Guggenheim raised their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at $11,548,950. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the sale, the director now directly owns 131,553 shares in the company, valued at $6,318,490.59. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,398 shares of company stock valued at $4,376,163 in the last ninety days. Insiders own 21.70% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new position in Vera Therapeutics in the second quarter valued at approximately $135,000. Ameritas Investment Partners Inc. raised its holdings in Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after buying an additional 688 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vera Therapeutics in the second quarter valued at approximately $163,000. Finally, Cetera Advisors LLC purchased a new position in Vera Therapeutics in the first quarter valued at approximately $235,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

Shares of VERA opened at $49.43 on Thursday. The company has a 50-day simple moving average of $42.17 and a 200-day simple moving average of $39.36. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $2.71 billion, a PE ratio of -18.94 and a beta of 1.03. Vera Therapeutics has a 52-week low of $12.28 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Equities research analysts predict that Vera Therapeutics will post -2.8 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.